Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadoline

Get ready for a showdown in the irritable bowel syndrome market. Valeant Pharmaceuticals ($VRX) is set to hear from the FDA this week on a new, broader use in IBS-D for Xifaxan, a drug it bought along with Salix last month. And next week, Actavis ($ACT) expects the FDA to say yea or nay to its IBS-D med eluxadoline, developed by Furiex, a company it bought last July. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.